U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H12N3PS
Molecular Weight 189.218
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THIOTEPA

SMILES

S=P(N1CC1)(N2CC2)N3CC3

InChI

InChIKey=FOCVUCIESVLUNU-UHFFFAOYSA-N
InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2

HIDE SMILES / InChI

Molecular Formula C6H12N3PS
Molecular Weight 189.218
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.drugbank.ca/drugs/DB04572

N,N’N’-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N’,N’’- triethylenephosphoramide (TEPA). The radiomimetic action of thiotepa is believed to occur through the release of ethylenimine radicals which, like irradiation, disrupt the bonds of DNA. One of the principal bond disruptions is initiated by alkylation of guanine at the N-7 position, which severs the linkage between the purine base and the sugar and liberates alkylated guanines. Thiotepa has been used in the palliation of a wide variety of neoplastic diseases. The more consistent results have been seen in: adenocarcinoma of the breast, adenocarcinoma of the ovary, superficial papillary carcinoma of the urinary bladder and for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THIOTEPA

Approved Use

Adenocarcinoma of the breast.

Launch Date

-3.41366407E11
Primary
THIOTEPA

Approved Use

Adenocarcinoma of the ovary.

Launch Date

-3.41366407E11
Primary
THIOTEPA

Approved Use

For the treatment of superficial papillary carcinoma of the urinary bladder

Launch Date

-3.41366407E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.91 μg/mL
200 mg/m² single, intravenous
dose: 200 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
THIOTEPA plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
28.24 μg × h/mL
200 mg/m² single, intravenous
dose: 200 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
THIOTEPA plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.15 h
200 mg/m² single, intravenous
dose: 200 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
THIOTEPA plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.55 h
20 mg/m² unknown, intravenous
dose: 20 mg/m²
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
THIOTEPA unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
20 mg/m² unknown, intravenous
dose: 20 mg/m²
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
THIOTEPA unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
65 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 65 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 65 mg/m2, 1 times / 3 weeks
Sources: Page: p.3172
unhealthy, 25-74
n = 8
Health Status: unhealthy
Condition: Cancer
Age Group: 25-74
Sex: M+F
Population Size: 8
Sources: Page: p.3172
Other AEs: Leukopenia, Thrombocytopenia...
Other AEs:
Leukopenia (grade 3, 25%)
Thrombocytopenia (grade 4, 12.5%)
Sources: Page: p.3172
75 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 75 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 75 mg/m2, 1 times / 3 weeks
Sources: Page: p.3172
unhealthy, 25-74
n = 7
Health Status: unhealthy
Condition: Cancer
Age Group: 25-74
Sex: M+F
Population Size: 7
Sources: Page: p.3172
DLT: Leukopenia, Thrombocytopenia...
Dose limiting toxicities:
Leukopenia (grade 3, 28.6%)
Thrombocytopenia (grade 3, 28.6%)
Thrombocytopenia (grade 4, 28.6%)
Sources: Page: p.3172
750 mg/m2 2 times / day multiple, intravenous (total)
MTD
Dose: 750 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 750 mg/m2, 2 times / day
Co-administed with::
Busulfan, p.o(30 mg/m(2); 4 times/day; 4 days)
Etoposide. i.v.(800 mg/m(2); q.d; 3 days)
Sources: Page: p.453
unhealthy, 2–16
n = 6
Health Status: unhealthy
Condition: Disseminated solid tumors
Age Group: 2–16
Sex: M+F
Population Size: 6
Sources: Page: p.453
Other AEs: Mucositis, Gastrointestinal toxicity...
Other AEs:
Mucositis (grade 3, 33.3%)
Gastrointestinal toxicity (grade 3, 33.3%)
Sources: Page: p.453
60 mg/m2 1 times / month multiple, intravenous
MTD
Dose: 60 mg/m2, 1 times / month
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / month
Co-administed with::
pentoxifylline, p.o(1600 mg; t.i.d; 4 doses)
Sources: Page: p.793
unhealthy, 30-76
n = 25
Health Status: unhealthy
Condition: Breast cancer
Age Group: 30-76
Sex: F
Population Size: 25
Sources: Page: p.793
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 3, 16%)
Leukopenia (grade 4, 8%)
Thrombocytopenia (grade 3, 16%)
Thrombocytopenia (grade 4, 12%)
Sources: Page: p.793
5 mg/kg 2 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 2 times / day
Co-administed with::
Busulfan, I.V(weight-based dose)
Cyclophosphamide, I.V(40 mg/kg/day)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Class 3 Beta-Thalassemia
Sources: Page: p.1
Disc. AE: Myelosuppression, Bone marrow failure...
AEs leading to
discontinuation/dose reduction:
Myelosuppression (severe)
Bone marrow failure (severe)
Disorder fetal
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Leukopenia grade 3, 25%
65 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 65 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 65 mg/m2, 1 times / 3 weeks
Sources: Page: p.3172
unhealthy, 25-74
n = 8
Health Status: unhealthy
Condition: Cancer
Age Group: 25-74
Sex: M+F
Population Size: 8
Sources: Page: p.3172
Thrombocytopenia grade 4, 12.5%
65 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 65 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 65 mg/m2, 1 times / 3 weeks
Sources: Page: p.3172
unhealthy, 25-74
n = 8
Health Status: unhealthy
Condition: Cancer
Age Group: 25-74
Sex: M+F
Population Size: 8
Sources: Page: p.3172
Leukopenia grade 3, 28.6%
DLT
75 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 75 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 75 mg/m2, 1 times / 3 weeks
Sources: Page: p.3172
unhealthy, 25-74
n = 7
Health Status: unhealthy
Condition: Cancer
Age Group: 25-74
Sex: M+F
Population Size: 7
Sources: Page: p.3172
Thrombocytopenia grade 3, 28.6%
DLT
75 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 75 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 75 mg/m2, 1 times / 3 weeks
Sources: Page: p.3172
unhealthy, 25-74
n = 7
Health Status: unhealthy
Condition: Cancer
Age Group: 25-74
Sex: M+F
Population Size: 7
Sources: Page: p.3172
Thrombocytopenia grade 4, 28.6%
DLT
75 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 75 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 75 mg/m2, 1 times / 3 weeks
Sources: Page: p.3172
unhealthy, 25-74
n = 7
Health Status: unhealthy
Condition: Cancer
Age Group: 25-74
Sex: M+F
Population Size: 7
Sources: Page: p.3172
Gastrointestinal toxicity grade 3, 33.3%
750 mg/m2 2 times / day multiple, intravenous (total)
MTD
Dose: 750 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 750 mg/m2, 2 times / day
Co-administed with::
Busulfan, p.o(30 mg/m(2); 4 times/day; 4 days)
Etoposide. i.v.(800 mg/m(2); q.d; 3 days)
Sources: Page: p.453
unhealthy, 2–16
n = 6
Health Status: unhealthy
Condition: Disseminated solid tumors
Age Group: 2–16
Sex: M+F
Population Size: 6
Sources: Page: p.453
Mucositis grade 3, 33.3%
750 mg/m2 2 times / day multiple, intravenous (total)
MTD
Dose: 750 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 750 mg/m2, 2 times / day
Co-administed with::
Busulfan, p.o(30 mg/m(2); 4 times/day; 4 days)
Etoposide. i.v.(800 mg/m(2); q.d; 3 days)
Sources: Page: p.453
unhealthy, 2–16
n = 6
Health Status: unhealthy
Condition: Disseminated solid tumors
Age Group: 2–16
Sex: M+F
Population Size: 6
Sources: Page: p.453
Leukopenia grade 3, 16%
60 mg/m2 1 times / month multiple, intravenous
MTD
Dose: 60 mg/m2, 1 times / month
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / month
Co-administed with::
pentoxifylline, p.o(1600 mg; t.i.d; 4 doses)
Sources: Page: p.793
unhealthy, 30-76
n = 25
Health Status: unhealthy
Condition: Breast cancer
Age Group: 30-76
Sex: F
Population Size: 25
Sources: Page: p.793
Thrombocytopenia grade 3, 16%
60 mg/m2 1 times / month multiple, intravenous
MTD
Dose: 60 mg/m2, 1 times / month
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / month
Co-administed with::
pentoxifylline, p.o(1600 mg; t.i.d; 4 doses)
Sources: Page: p.793
unhealthy, 30-76
n = 25
Health Status: unhealthy
Condition: Breast cancer
Age Group: 30-76
Sex: F
Population Size: 25
Sources: Page: p.793
Thrombocytopenia grade 4, 12%
60 mg/m2 1 times / month multiple, intravenous
MTD
Dose: 60 mg/m2, 1 times / month
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / month
Co-administed with::
pentoxifylline, p.o(1600 mg; t.i.d; 4 doses)
Sources: Page: p.793
unhealthy, 30-76
n = 25
Health Status: unhealthy
Condition: Breast cancer
Age Group: 30-76
Sex: F
Population Size: 25
Sources: Page: p.793
Leukopenia grade 4, 8%
60 mg/m2 1 times / month multiple, intravenous
MTD
Dose: 60 mg/m2, 1 times / month
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / month
Co-administed with::
pentoxifylline, p.o(1600 mg; t.i.d; 4 doses)
Sources: Page: p.793
unhealthy, 30-76
n = 25
Health Status: unhealthy
Condition: Breast cancer
Age Group: 30-76
Sex: F
Population Size: 25
Sources: Page: p.793
Disorder fetal Disc. AE
5 mg/kg 2 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 2 times / day
Co-administed with::
Busulfan, I.V(weight-based dose)
Cyclophosphamide, I.V(40 mg/kg/day)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Class 3 Beta-Thalassemia
Sources: Page: p.1
Bone marrow failure severe
Disc. AE
5 mg/kg 2 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 2 times / day
Co-administed with::
Busulfan, I.V(weight-based dose)
Cyclophosphamide, I.V(40 mg/kg/day)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Class 3 Beta-Thalassemia
Sources: Page: p.1
Myelosuppression severe
Disc. AE
5 mg/kg 2 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 2 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 2 times / day
Co-administed with::
Busulfan, I.V(weight-based dose)
Cyclophosphamide, I.V(40 mg/kg/day)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Class 3 Beta-Thalassemia
Sources: Page: p.1
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
strong [Ki 4.8 uM]
likely (co-administration study)
Comment: noncompetitive inhibition. Ki value obtained using HLM; may increase the exposure of drugs that are substrates of CYP2B6 in patients; however, the clinical relevance of this in vitro interaction is unknown
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
likely (co-administration study)
Comment: Avoid coadministration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin); exposure to thiotepa was significantly reduced (29%) when coadministered with phenytoin (CYP inducer)
Page: 10.0
yes
weak (co-administration study)
Comment: exposure to thiotepa was significantly reduced (29%) when coadministered with phenytoin (CYP inducer);
Page: 10.0
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Renal failure associated with the use of thio-tepa.
1973 Nov
The morphologic effects of mitomycin C in mammalian urinary bladder.
1981 Jun 1
[Arsenic trioxide inhibition of the thiophosphamide induction of mutations in mouse germ and somatic cells].
1984 Feb
Systemic influence of intravesical chemotherapy with verapamil.
1985
Nephrogenic adenoma in a patient with chronic renal failure associated with intravesical treatment with thiotepa.
1990
Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies.
1990 Nov
Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.
1990 Oct
The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa.
1995 Apr 15
Intravesical thiotepa-induced eosinophilic cystitis.
1995 Nov
Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study.
1995 Sep 27
Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
1997 Nov-Dec
[A comparative study of thio-tepa and mitomycin C in the treatment of pterygium. Preliminary results].
1998 Feb
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
1999
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
1999 Apr 1
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
2000 Aug
[Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype].
2000 Jul
Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N',N"-triethylenethiophosphoramide (thioTEPA)-induced toxicity in vitro and in vivo.
2001 Jul 1
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.
2001 Sep
Sensitivity of p53-deficient cells to oxaliplatin and thio-TEPA (N, N', N" triethylenethiophosphoramide).
2002 Apr
Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
2002 Aug
Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.
2002 May
Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli.
2002 Oct
A novel case of a CAT to AAT transversion in codon 179 of the p53 gene in a supratentorial primitive neuroectodermal tumor harbored by a young girl. Case report and review of the literature.
2003
In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
2003 Nov
Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
2004 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation.
2005 Jun
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.
2006 Apr
Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
2006 Dec
The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity.
2008 Aug 11
Wound healing in patients with cancer.
2008 Jan 11
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
2008 Nov
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
2008 Oct
Breast cancer management: the road to today.
2008 Oct 1
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
2009 Jan
Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.
2009 Jun
Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.
2010 Apr
Nicotinamide inhibits alkylating agent-induced apoptotic neurodegeneration in the developing rat brain.
2011
Zebrafish (Danio rerio) embryos as a model for testing proteratogens.
2011 Mar 15
Efficient monitoring of in vivo pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds.
2012 Dec
Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
2013 Sep 5
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Intracavitary Administration: The dosage recommended is 0.6 to 0.8 ug/kg. Administration is usually effected through the same tubing which is used to remove the fluid from the cavity involved.
Thiotepa may be given by rapid intravenous administration in doses of 0.3 to 0.4 ug/kg. Doses should be given at 1 to 4 week intervals.
Route of Administration: Intravenous
In Vitro Use Guide
The cytotoxicity of thiotepa toward MCF-7 cells was markedly dependent on the presence of oxygen during the period of drug exposure, with a 3-log greater cell kill at 500 umol with cells that were normally oxygenated compared with hypoxic cells.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:43:40 UTC 2023
Edited
by admin
on Wed Jul 05 22:43:40 UTC 2023
Record UNII
905Z5W3GKH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THIOTEPA
EMA EPAR   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
thiotepa [INN]
Common Name English
TRIS(1-AZIRIDINYL)PHOSPHINE SULFIDE
Systematic Name English
THIOTEPA [USP MONOGRAPH]
Common Name English
1,1',1''-PHOSPHOROTHIOYLTRIAZIRIDINE
Systematic Name English
NSC-6396
Code English
THIOTEPA [ORANGE BOOK]
Common Name English
AZIRIDINE,1,1',1''-PHOSPHINOTHIOYLIDYNETRIS-
Common Name English
THIOTEPA [MART.]
Common Name English
Thiotepa [WHO-DD]
Common Name English
1,1',1''-PHOSPHINOTHIOYLIDYNETRIS(AZIRIDINE)
Common Name English
THIOTEPA [MI]
Common Name English
THIOTEPA [JAN]
Common Name English
TEPADINA
Brand Name English
THIOPLEX
Brand Name English
THIOTEPA [HSDB]
Common Name English
THIOTEPA [IARC]
Common Name English
THIOTEPA [EMA EPAR]
Common Name English
THIOTEPA [VANDF]
Common Name English
THIOTEPA [USP-RS]
Common Name English
PHOSPHOROTHIOIC TRI(ETHYLENEAMIDE)
Common Name English
Classification Tree Code System Code
IARC Thiotepa
WHO-ATC L01AC01
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
EU-Orphan Drug EU/3/06/424
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
NCI_THESAURUS C292
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
NDF-RT N0000175558
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
LIVERTOX NBK548174
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
EMA ASSESSMENT REPORTS TEPADINA (AUTHORIZED: HEMATOPOIETIC STEM CELL TRANSPLANTATION)
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
NDF-RT N0000000236
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
FDA ORPHAN DRUG 237807
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
WHO-VATC QL01AC01
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
Code System Code Type Description
RS_ITEM_NUM
1664000
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
FDA UNII
905Z5W3GKH
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
DRUG CENTRAL
2638
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
SMS_ID
100000082128
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
MESH
D013852
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
HSDB
3258
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
MERCK INDEX
M10788
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
200-135-7
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
NSC
6396
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
WIKIPEDIA
Thiotepa
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
EPA CompTox
DTXSID0021339
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
INN
881
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
DRUG BANK
DB04572
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
PUBCHEM
5453
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
RXCUI
10473
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY RxNorm
CAS
52-24-4
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
NCI_THESAURUS
C875
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
ChEMBL
CHEMBL671
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
DAILYMED
905Z5W3GKH
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
ALANWOOD
thiotepa
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
EVMPD
SUB10985MIG
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
IUPHAR
7622
Created by admin on Wed Jul 05 22:43:40 UTC 2023 , Edited by admin on Wed Jul 05 22:43:40 UTC 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY